Remove Biotechnology Remove Development Remove Licensing
article thumbnail

Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics

GeekWire

Sana Biotechnology has a new $50 million tool in its toolbox. Beam may also receive additional payments, for instance upon the achievement of development and sales milestones. Sana aims to develop therapeutics for conditions as diverse as cancer, diabetes and cardiovascular disorders. Sana CEO and president Steve Harr.

article thumbnail

Cyrus Biotech spins out company to expand reach of versatile drug development software

GeekWire

Levitate Bio’s CEO Sam DeLuca, left, and Karen Khar, executive vice president of sales and business development. The University of Washington has issued more than 60,000 non-commercial licenses to Rosetta users, and more than 200 licenses to commercial organizations. Tech companies are really good at what they do.

Software 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch

GeekWire

Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. The company, a spin-out from the UW’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Icosavax Photo).

article thumbnail

Mars Society gains foothold in AI, robotics and biotechnology to clear a path to space

GeekWire

To make a profit, yes, but also to support the development of technologies needed to sustain settlements on the Red Planet. “Those inventions — as it were, IP as exports from Mars — will be one of the main economic supports of the Mars city-state,” Zubrin said.

article thumbnail

Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M

GeekWire

Seattle-based cell therapy startup Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system in a deal worth potentially more than $900 million. Immusoft CEO Sean Ainsworth. Immusoft Photo). Immusoft closed a $33 million Series B round last year, noted FierceBiotech.

article thumbnail

Life sciences startups in Eastern Washington find a welcoming ecosystem away from big cities

GeekWire

Washington State University assistant professor and Appiture Biotechnologies co-founder Georgina Lynch. Hojah received funding from Simpson and other backers to launch his eight-employee startup developing assistive technologies for people with multiple sclerosis and other conditions. WSU Photo).

article thumbnail

Seattle biotech startup AltPep raises $23.1M to tackle Alzheimer’s and related diseases

GeekWire

AltPep is developing tools and treatments for diseases caused by amyloid proteins that are incorrectly folded and create harmful deposits. The UW has licensed the exclusive rights of this intellectual property to the startup. Another Seattle-area biotech startup, Athira Pharma, is also developing treatments for Alzheimer’s.